Clinical Trial Update: A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB) [Phase 2]

View source ↗

Summary

Phase II study evaluating the combination of tucatinib and ado-trastuzumab emtansine (T-DM1) in HER2-positive metastatic solid tumors with brain metastases; cur…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Solid Tumor

Drugs mentioned

• Kadcyla (ado-trastuzumab emtansine)
• Tucatinib (tucatinib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Metastatic Solid Tumor, Brain Metastases | Phase 2 | Status: RECRUITING